Metabolic Enzyme ME1 Emerges as Key to Unlocking Progestin Therapy in Endometrial Cancer Bioengineer.org
Metabolic Enzyme ME1 Emerges as Key to Unlocking Progestin Therapy in Endometrial Cancer bioengineer.org
Endometriosis is a common gynecological disease in which lipid metabolic dysregulation has been increasingly implicated. However, the specific metabolic changes in ectopic lesions and stromal cells remain poorly understood. It …
Cholesterol Enzyme DHCR24 Emerges as Driver and Biomarker of Endometrial Cancer Bioengineer.org
Cholesterol Enzyme DHCR24 Emerges as Driver and Biomarker of Endometrial Cancer bioengineer.org
Endometriosis (EMS) is a chronic inflammatory disease affecting 10%-15% of women of reproductive age and is a major cause of infertility. This study explores the therapeutic effects of linalool, a …
β-Glucuronidase (β-G, EC 3.2.1.31) reverses phase II glucuronidation, and microbial β-G at the gut-liver interface reactivates biliary and circulating conjugates, closing enterohepatic loops for drugs, estrogens, bile acids, and bilirubin. …
Endometriosis causes pelvic pain, dysmenorrhea (DYS), dyspareunia, and fertility issues. Linustedastat (OG-6219) is an oral, selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (HSD17β1), an enzyme involved in local estradiol biosynthesis. …
Endometriosis is a chronic inflammatory condition that affects an estimated 1 in 10 women but is often mis- and underdiagnosed due to its non-specific symptoms and the lack of a …
Does pyruvate carboxylase drive the progression of endometriosis, and, if so, what is the underlying mechanism?